Keybank National Association OH Buys 8,853 Shares of DexCom, Inc. (NASDAQ:DXCM)

Keybank National Association OH boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 101.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,585 shares of the medical device company’s stock after acquiring an additional 8,853 shares during the period. Keybank National Association OH’s holdings in DexCom were worth $1,368,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Versant Capital Management Inc purchased a new position in shares of DexCom during the fourth quarter valued at about $25,000. Private Trust Co. NA boosted its stake in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares during the last quarter. Heck Capital Advisors LLC bought a new position in DexCom during the fourth quarter valued at approximately $38,000. SBI Securities Co. Ltd. purchased a new position in DexCom during the 4th quarter valued at approximately $49,000. Finally, Midwest Capital Advisors LLC bought a new stake in DexCom in the 4th quarter worth approximately $54,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of DexCom stock opened at $77.84 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a market capitalization of $30.42 billion, a PE ratio of 54.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The stock’s fifty day moving average is $84.83 and its two-hundred day moving average is $76.96. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research reports. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Wells Fargo & Company increased their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Citigroup lifted their price target on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,083 shares of company stock valued at $3,309,794. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.